Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.55 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4312066 | 0.85 | THRA (0.52) | EPHX2ALDH1A1MAPTGAAAGTR1 | |
| SCHEMBL29894695 | 0.84 | FABP4 (0.56) | CYP3A4NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL29499460 | 0.84 | FFAR1 (0.46) | ALDH1A1MAPTGAAAGTR1SMN1; SMN2 | |
| SCHEMBL1434153 | 0.84 | FFAR1 (0.46) | ALDH1A1MAPTGAAAGTR1SMN1; SMN2 | |
| SCHEMBL2728813 | 0.84 | FABP4 (0.56) | CYP3A4NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL31028751 | 0.84 | ALDH1A1 (0.70) | NPC1ALDH1A1MAPTRAB9AGAA | |
| SCHEMBL11006722 | 0.83 | CYP3A4 (0.54) | EPHX1EPHX2CYP3A4NPC1ALDH1A1 | |
| SCHEMBL1930556 | 0.82 | SMN1; SMN2 (0.46) | ALDH1A1MAPTRAB9AGAAAGTR1 | |
| SCHEMBL11432298 | 0.81 | CA2 (0.56) | EPHX1EPHX2CYP3A4NPC1ALDH1A1 | |
| SCHEMBL1847384 | 0.81 | FFAR1 (0.55) | EPHX1EPHX2CYP3A4NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114906-B1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS FOR CNS DISORDERS | HOFFMANN LA ROCHE (CH) | 2014-08-06 | — | — | EP | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-8754107-B2 | Aminopyrrolidines as chemokine receptor antagonists | ABBVIE INC. (US) | 2014-06-17 | — | — | US | disclosed |
| CN-102112451-B | Diazepan and piperazine derivatives modulators of chemokine receptors | HOFFMANN LA ROCHE | 2014-01-22 | — | — | CN | disclosed |
| US-8604061-B2 | 2-aminooxazolines as TAAR1 ligands | HOFFMANN-LA ROCHE INC. (US) | 2013-12-10 | — | — | US | disclosed |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO (DE) | 2012-08-02 | — | — | US | disclosed |
| US-8138175-B2 | Heterocyclyl compounds | HOFFMANN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2321285-A1 | DIAZEPAN AND PIPERAZINE DERIVATIVES MODULATORS OF CHEMOKINE RECEPTORS | F. Hoffmann-La Roche AG (CH) | 2011-05-18 | — | — | EP | disclosed |
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | GALLEY GUIDO | 2010-05-13 | — | — | US | disclosed |
| EP-0254578-A1 | Antibiotic intermediates | ELI LILLY AND COMPANY (US) | 1988-01-27 | — | — | EP | disclosed |
| US-4225617-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-09-30 | — | — | US | disclosed |
| US-4210612-A | LIGHT STABILIZERS FOR PLASTICS | CIBA-GEIGY CORPORATION (US) | 1980-07-01 | — | — | US | disclosed |
| US-4209524-A | CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4209523-A | TREATMENT OF THE CENTRAL NERVOUS SYSTEM | LABORATOIRE L. LAFON (FR) | 1980-06-24 | — | — | US | disclosed |
| US-4183951-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1980-01-15 | — | — | US | disclosed |
| US-4152458-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1979-05-01 | — | — | US | disclosed |
| US-4151300-A | CENTRAL NERVOUS SYSTEM, PSYCHOTROPIC | LABORATOIRE L. LAFON (FR) | 1979-04-24 | — | — | US | disclosed |
| US-4122186-A | PSYCHOTROPIC AGENTS | LABORATOIRE L. LAFON (FR) | 1978-10-24 | — | — | US | disclosed |
| US-4065620-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120864-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | EPHX1 897/4885EPHX2 1373/4885CYP3A4 790/4885 |
| US-20120196903-A1 | 2-AMINOOXAZOLINES AS TAAR1 LIGANDS | TAAR1, TAAR5, NPY2R | EPHX1 1044/4885EPHX2 1321/4885CYP3A4 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.